1. Contingent liability
 
 a. The Company has issued corporate guarantee in favour of state Bank
 of india, state Bank of travancore, iCiCi Bank Ltd., indusind Bank Ltd.
 and HdFC Bank Ltd. against line of credit sanctioned to advanced
 micronic devices Ltd., Opto eurocor Healthcare Ltd., eurocor GmbH and
 Cardiac science Corporation.
 
                                                             Rs. in Lacs
 
 Particulars                                31.03.2011        31.03.2010
 
 Corporate guarantee-                         1,701.00          1,787.00
 advance micronic devices Ltd.
 
 Corporate guarantee-Opto                     5,000.00          3,400.00
 Eurocor Healthcare Ltd.
 
 Corporate guarantee-Eurocor                  3,162.00             –
 
 GMBH
 
 Corporate guarantee–                         6,697.50             –
 
 Cardiac science Corporation
 
 TOTAL                                       16,560.50          5,187.00
 
 b. Bank guarantees issued on behalf of the Company to Banks is rs.
 125.00 lacs
 
 2. Funding for share Acquisition the Company has established a
 corporate guarantee of rs.  13,395.00 lacs against loan extended by dBs
 bank for investment in Cardiac science Corporation, usa. the Loan was
 obtained by Jolt acquisition Company, a wholly owned subsidiary for
 acquisition of shares and subsequent to the acquisition, Jolt
 acquisition Company merged with Cardiac science Corporation, usa. since
 the loan was raised for acquisition of shares of Cardiac science
 Corporation, the liability towards the loan and corresponding
 investments in shares are accounted in Opto Circuits (india) Ltd.
 
 3. During the year ended 31st march 2011, the Company has made the
 following acquisitions:
 
 - N. S. remedies pvt. Ltd., a stent manufacturing and research
 development facility in april 2010 at the total cost of rs. 600 lacs.
 
 - Unetixs Vascular, inc., a specialist in detection of peripheral
 arterial diseases in July 2010 at the total cost of rs. 4,533 lacs
 
 - Cardiac science Corporation which is a leading manufacturer of
 therapeutic cardiology devices in december 2010 for rs.  40,858.84
 lacs.
 
 4. The income tax department has raised a demand for tax of rs.  14.16
 lacs for the aY 2004-05 for which the Company has preferred an appeal
 before the Commissioner of income tax (appeal) iii.  pending disposal
 of this, the Company has not provided liability for income tax.
 
 5. Deferred tax is recognized on timing differences between the
 accounting income and the taxable income for the current year and is
 quantifed using the tax rates for unit ii. For the sez unit, deferred
 tax asset has not been recognized as there is no virtual certainty
 supported by convincing evidence that suffcient future taxable income
 will be available for such deferred tax asset to be set off. tax
 expenses towards deferred tax liability do not arise for the seZ unit
 as income is covered under section 10aa of the income tax act, 1961.
 
 6. Product development expenses product development expenses that are
 not charged off to the profit and loss account are refected under the
 head miscellaneous expenditure (to the extent not written off or
 adjusted) in the Balance sheet. this amount is amortised over the
 estimated useful life of product development expenses. during this year
 an amount of rs. 366.05 lacs has been charged to profit and loss
 account as product development comprising rs 179.85 lacs incurred
 during this year and rs 186.20 lacs capitalised in the earlier years.
 
 7. Segment wise reporting
 
 a.  The Company has mainly one business segment of medical electronic
 products.
 
 b.  The Company has geographical region wise segments of customers as
 shown below, region wise profitability can not be ascertained.
 
 1.  Segments have been identified in accordance with accounting standard
 17 segment reporting, considering the organization structure & the
 return/risk profiles of the businesses. the management information
 system recognizes & monitors these segments on a continuous basis.
 
 2.  Segment wise revenue includes sales & other income directly
 identifable with the segment & allocated to it. assets used in the
 Company''s business or liabilities contracted have not been identified to
 any of the reportable segments.
 
 8. Table below shows the proceeds from share warrants during the year
 2010-11. these share warrants were issued in July 2009 and the issue
 price was rs.210 per warrant.
 
 In July 2009, the Company had issued 60.00 lac equity warrants at rs.
 210 per share with each warrant convertible into one equity share of
 the Company, out of which 46.79 lac share warrants had been subscribed.
 the Company had received rs. 52.50 for each warrant which is 25% of the
 issue price from the allottees of the share warrant holders.
 
 During the current financial year, out of 46.79 lac shares warrants,
 35.00 lac share warrants were opted for conversion by paying the
 balance amount of rs. 5,512.50 lacs and 35.00 lac equity share were
 allotted to the warrant holders. the remaining 11.79 lac share warrants
 lapsed and were consequently forfeited and the amount paid by the
 warrant holders amounting to rs. 618.97 lacs is transferred to Capital
 reserve account.
 
 9. Related party disculosure:
 
 List of related parties where Company''s management control exists
 
 a. subsidiaries
 
 Name of the Company
 
 1. advanced micronic devices Ltd.
 
 2. mediaid, inc.
 
 3. eurocor GmbH
 
 4. devon innovations pvt. Ltd.
 
 5. Ormed medical technology Ltd.
 
 6. Criticare systems, inc.
 
 7. Opto infrastructure Ltd.
 
 8. maxcor Lifescience inc.
 
 9. n.s. remedies pvt. Ltd.
 
 10. Opto Circuits (malaysia)sdn. Bhd.
 
 11.unetixs Vascular, inc.
 
 12. Cardiac science Corporation
 
 13. Opto Cardiac Care Ltd.
 
 14. Opto eurocor Healthcare Ltd.
 
 b. Key management personnel
 
 Name of related party                       Relationship
 
 Vinod Ramnani                         Key management personnel
 
 Usha Ramnani                          Key management personnel
 
 Jayesh C Patel                        Key management personnel
 
 Thomas dietiker                       Key management personnel
 
 10. Dividend paid in foreign currency for the year 2009-10 is usd 9.41
 lacs towards 101.36 lac equity shares held by nris, foreign nationals
 and Fiis.
 
 11. Previous year fgures have been regrouped & reclassified to
 correspond with the current year''s classifcation.